AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18705977
Drug: Regular implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular implementation strategy for intravenous thrombolysis
Trial: 8979328
Drug: Conventional transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional transfusion therapy (retrospective cohort)
Trial: 30595357
Drug: PCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI with new-generation drug-eluting stents (DES)
Trial: 21414045
Drug: HVP (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVP (5-15 g per day)
Trial: 19669067
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy (16 semi-structured sessions)
Trial: 31957479
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy
Trial: 11485143
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride (monotherapy) at doses of 1.5-4.5 g once daily or in two divided doses
Trial: 11485143
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride combined with HMG-CoA reductase inhibitor
Trial: 11485143
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride (monotherapy)
Trial: 8097921
Drug: Abecarnil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abecarnil 20 mg
Trial: 8097921
Drug: Abecarnil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abecarnil 40 mg
Trial: 29868998
Drug: Behavioral drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral drug abuse treatment (intervention)
Trial: 22943586
Drug: Pulse lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse lavage therapy at 10 to 15 psi pressure
Trial: 20533373
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg rhFGF-2 (low-dosage group)
Trial: 20533373
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg rhFGF-2 (high-dosage group)
Trial: 20533373
Drug: Low-dosage group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage group
Trial: 20533373
Drug: High-dosage group
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage group
Trial: 16422854
Drug: Sildenafil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil plus continuous testosterone undecanoate therapy (TRT) in group 1ST
Trial: 16422854
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate therapy (TRT) alone in group 1T
Trial: 9801742
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 64 micrograms, 128 micrograms, 256 micrograms
Trial: 9801742
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 128 micrograms, 256 micrograms
Trial: 9801742
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 256 micrograms
Trial: 9801742
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide aqueous pump spray (Rhinocort Aqua)
Trial: 25972527
Drug: Epicatechin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicatechin (100 mg/d)
Trial: 25972527
Drug: Quercetin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (160 mg/d)
Trial: 16428266
Drug: H pylori
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori eradication therapy (group 1, n = 41)
Trial: 16428266
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group 2, n = 40)
Trial: 1348079
Drug: Recombinant interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha (1, 3, or 5 million units thrice weekly for 4 or 6 months)
Trial: 18312543
Drug: Tolterodine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (4 mg daily for 6 days)
Trial: 16550731
Drug: DOX GITS
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOX GITS (4 mg/d)
Trial: 16550731
Drug: DOX-S4 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOX-S4 (4 mg/d)
Trial: 16550731
Drug: DOX-S2 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOX-S2 (2 mg/d)
Trial: 12606887
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (1200 mg of elemental calcium daily)
Trial: 1478293
Drug: Polyadenylic-polyuridylic acid
RxNorm normalized name: polyacrylic acid (450000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyadenylic-polyuridylic acid (AU), one i.v. injection of 60 mg (in 50 ml of solution) once a week for 6 weeks
Trial: 1478293
Drug: Placebo (P),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P), one i.v. injection of 50 ml of saline solution with the same schedule
Trial: 29690924
Drug: Regularly dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly dosed paracetamol
Trial: 23893147
Drug: Intradiscal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal and intraforaminal injection of oxygen‐ozone
Trial: 23893147
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of oxygen‐ozone combined with 1ml of compound betamethasone
Trial: 18829998
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (150 mg)
Trial: 14604715
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with microkeratome blades wiped with balanced salt solution (BSS)
Trial: 8742282
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional anesthesia
Trial: 25850750
Drug: Selexipag (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (400 μg single dose)
Trial: 25850750
Drug: Selexipag (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (600 μg multiple doses)
Trial: 25850750
Drug: Selexipag (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selexipag (400 μg open-label dose)
Trial: 23944767
Drug: Nonsynonymous m.10398A>G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsynonymous m.10398A>G mtDNA polymorphism (N=8)
Trial: 17223112
Drug: rosuvastatin (across
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (across dose range)
Trial: 15470853
Drug: Kinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic therapy (systematic mechanical rotation of patients with 40 degree turns)
Trial: 7915703
Drug: Short-term prazosin
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term prazosin (2 mg orally)
Trial: 7915703
Drug: Long-term prazosin
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term prazosin (5 mg/12 hr for 3 months)
Trial: 769595
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine 0-3 mg given prior to surgery
Trial: 769595
Drug: Droperidol 0-1
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol 0-1 mg/kg
Trial: 769595
Drug: Atropine 0-6
RxNorm normalized name: atropine sulfate 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0-6 mg intramuscularly followed by controlled ventilation
Trial: 28926521
Drug: TNT009 (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNT009 (7 consecutive cohorts, 0.3-100 mg/kg single doses)
Trial: 28926521
Drug: TNT009 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNT009 (2 consecutive cohorts, 30 and 60 mg/kg per infusion, 4 weekly infusions)
Trial: 24215780
Drug: Xylazine (1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine (1mg/kg IV bolus followed by 0.69 mg/kg/h IV CRI for 2h)
Trial: 24215780
Drug: Romifidine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romifidine (80 μg/kg IV bolus followed by 30 μg/kg/h IV CRI for 2h)
Trial: 17106926
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACE-I; Perindopril 4 mg/d)
Trial: 17106926
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with interferon (IFN; 3 MU/L; 3 times a week) and ACE-I
Trial: 17106926
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with ACE-I and IFN
Trial: 11379810
Drug: BDP-extrafine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP-extrafine (400 microg daily)
Trial: 11379810
Drug: FP (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP (400 microg daily)
Trial: 7955168
Drug: Albendazole candy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole candy 100 mg (single dose)
Trial: 7955168
Drug: Albendazole 150
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 150 mg qd for two days
Trial: 7955168
Drug: Albendazole 200
RxNorm normalized name: albendazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 200 mg qd for two days
Trial: 24418865
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment combined with 1% olopatadine ophthalmic solution
Trial: 24418865
Drug: 0.03% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% tacrolimus ointment combined with placebo eye drops
Trial: 21039763
Drug: Pharmaceutical products
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical products with active substances classified by BCS
Trial: 21039763
Drug: Pharmaceutical products
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical products with intra-subject variability higher than predicted
Trial: 21039763
Drug: Comparisons between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparisons between pharmaceutical products from the four BCS classes
Trial: 17060064
Drug: Angiotensin blocker
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin blocker (valsartan)
Trial: 17060064
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (diltiazem monotherapy)
Trial: 10936118
Drug: Salmeterol (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (42 microg) every 12 h in addition to standard therapy
Trial: 10936118
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two puffs every 12 h) in addition to standard therapy
Trial: 18590407
Drug: NSAIDs in
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs in addition to opioid analgesics
Trial: 17136232
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 0.5% lidocaine plus 20 mg propofol (Group P)
Trial: 17136232
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 0.5% lidocaine (Group C)
Trial: 10682869
Drug: Carbohydrate supplements
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplements
Trial: 7595746
Drug: Etopophos (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etopophos (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Trial: 7595746
Drug: VePesid (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VePesid (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Trial: 2275328
Drug: Flunitrazepam (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.04 mg.kg‐1)
Trial: 7001862
Drug: Alprenolol (non-selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (non-selective beta-blocker)
Trial: 7001862
Drug: Metoprolol (cardioselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (cardioselective beta 1-blocker)
Trial: 17259500
Drug: Boric acid
RxNorm normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boric acid vaginal suppositories (600 mg/day for 14 days)
Trial: 17259500
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (150 mg single dose)
Trial: 17259500
Drug: Clinical symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical symptoms and signs of VVC on the 15th day of treatment
Trial: 7823668
Drug: Two blocks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two blocks of additional intensification therapy
Trial: 7823668
Drug: One block
RxNorm normalized name: Adrenergic neurone blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One block of intensification therapy at 5 weeks
Trial: 7823668
Drug: One block
RxNorm normalized name: Adrenergic neurone blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One block of intensification therapy at 20 weeks
Trial: 7823668
Drug: No intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intensification therapy
Trial: 2688033
Drug: Active specific
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active specific immunotherapy (ASI) with an autologous tumor cell‐BCG vaccine
Trial: 803910
Drug: Conventional plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional plus vasopressin therapy
Trial: 31207009
Drug: Intermittent intrauterine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intrauterine balloon dilatation therapy at 2 weeks and 6 weeks after surgery
Trial: 31207009
Drug: Intermittent intrauterine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intrauterine balloon dilatation therapy
Trial: 23933032
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination capsule of Alfuzosin hydrochloride 10mg extended release and Solifenacin succinate 5mg
Trial: 23933032
Drug: Individually administered
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually administered Xatral XL 10mg tablets (Alfuzosin) and Vesicare 5mg tablets (Solifenacin)
Trial: 11043547
Drug: Repetitive peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive peripheral magnetic stimulation (RPMS) treatment of the left forearm
Trial: 9432635
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg q.d. for 2 or 4 weeks)
Trial: 9432635
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg q.d. for 2 or 4 weeks)
Trial: 3885915
Drug: methylprednisolone, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone, 30 mg/kg, every six hours for 48 hours
Trial: 31785387
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) - four applications
Trial: 31785387
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metronidazole (MTZ) and amoxicillin (AMX) - 3 tablets each for 7 days
Trial: 29437170
Drug: Sacha inchi
RxNorm normalized name: Abies sachalinensis var. sachalinensis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacha inchi oil (15 mL)
Trial: 22111353
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume group (7 ml x kg(‐1) predicted body weight), n = 8
Trial: 22111353
Drug: Conventional tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tidal volume group (10 ml x kg(‐1) predicted body weight), n = 8
Trial: 17393617
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with drugs (treatment group)
Trial: 11472316
Drug: Fructo oligosaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructo oligosaccharides (10 g daily)
Trial: 9935261
Drug: Intravenous alatrofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alatrofloxacin (200 or 300 mg/day) followed by oral trovafloxacin (200 mg/day)
Trial: 9935261
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous or oral prophylaxis with alatrofloxacin or trovafloxacin
Trial: 8186345
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine (5-aminosalicylic acid) 2.4 g/day
Trial: 3364822
Drug: Methoxamine 10
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 10 mg
Trial: 554446
Drug: Thioridazine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (100 to 600 mg daily)
Trial: 554446
Drug: Drug holidays
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug holidays
Trial: 26262996
Drug: Sublingual GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual GSH
Trial: 26262996
Drug: Oral GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GSH
Trial: 18818130
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with cytokine-induced killer cells for 3 courses (CIK-I group)
Trial: 18818130
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with cytokine-induced killer cells for 6 courses (CIK-II group)
Trial: 11461949
Drug: Conventional-dose CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CsA (target trough level 300 ng/ml)
Trial: 11461949
Drug: Low-dose CsA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CsA (target trough level 150 ng/ml)
Trial: 11461949
Drug: Conventional-dose CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CsA
Trial: 11461949
Drug: Low-dose CsA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CsA
Trial: 2855478
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2 litres, 0.9% NaCl) over 60 min
Trial: 25577189
Drug: Dissonance‐based Counter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dissonance‐based Counter Attitudinal Therapy group treatment
Trial: 23727190
Drug: Add-on pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Add-on pregabalin at a dosage of 600 mg/day
Trial: 17255839
Drug: Lactoferrin-enhanced formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin-enhanced formula (850 mg/L)
Trial: 17255839
Drug: Regular formula
RxNorm normalized name: COMPLEAT REGULAR FORMULA LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular formula (102 mg/L)
Trial: 15284262
Drug: C+P (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+P (cisplatin 50 mg/m2 plus paclitaxel 135 mg/m2)
Trial: 15284262
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m2)